Malignant neoplasm of right ureter
ICD-10 C66.1 is a billable code used to indicate a diagnosis of malignant neoplasm of right ureter.
C66.1 refers to a malignant neoplasm located in the right ureter, which is part of the urinary tract responsible for transporting urine from the kidney to the bladder. This type of cancer can arise from the epithelial cells lining the ureter and may present with symptoms such as hematuria (blood in urine), flank pain, or urinary obstruction. Diagnosis typically involves imaging studies such as CT scans or MRIs, and may be confirmed through biopsy. Staging of the cancer is crucial for determining the appropriate treatment plan and involves assessing the tumor size, lymph node involvement, and presence of metastasis. Surgical management often includes ureterectomy, where the affected segment of the ureter is removed, and may be accompanied by lymphadenectomy if lymph nodes are involved. Adjuvant therapies, such as chemotherapy or radiation, may also be considered based on the stage and grade of the tumor. Accurate coding is essential for proper treatment reimbursement and tracking of cancer statistics.
Detailed operative reports, pathology reports, and imaging studies.
Diagnosis and management of ureteral tumors, post-operative follow-up, and complications.
Ensure accurate staging and documentation of any adjuvant therapies.
Comprehensive treatment plans, chemotherapy administration records, and follow-up assessments.
Management of metastatic disease, coordination of multi-disciplinary care, and palliative care considerations.
Document all treatment modalities and response to therapy for accurate coding.
Used when performing a surgical resection of the right ureter due to malignancy.
Operative report detailing the procedure and findings.
Urology specialists should ensure all surgical details are documented for accurate coding.
Common symptoms include hematuria, flank pain, and urinary obstruction. Patients may also experience changes in urinary habits.
Diagnosis typically involves imaging studies such as CT scans or MRIs, followed by biopsy to confirm malignancy.
Treatment often involves surgical resection of the affected ureter segment, with possible adjuvant chemotherapy or radiation therapy depending on staging.
